Study of liver inflammation and scarring in hepatitis B or fatty liver
Part of Digestive system, Infections clinical trials.
This study looks at what factors predict liver inflammation, scarring (fibrosis), and health outcomes in people with long-term hepatitis B or fatty liver disease. The goal is to better understand who is more likely to worsen over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years old or older
- Have hepatitis B surface antigen (HBsAg) positive for at least 6 months, and no other hepatitis viruses
- Have nonalcoholic fatty liver disease (NAFLD) confirmed by imaging, blood/predictive tests, or a liver biopsy
- Do not have other chronic liver causes (like alcohol-related liver disease, other viral hepatitis, or medicine-related liver injury)
- Have no history of liver cancer (HCC) or other cancers before your liver biopsy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who have chronic hepatitis B and also have fat buildup in the liver (nonalcoholic fatty liver disease). It’s looking at how these conditions behave over time and what may help, using information collected during follow-up visits.
This study tracks how liver scarring (fibrosis) and fat buildup (steatosis) change over time in people with nonalcoholic fatty liver disease (NAFLD). It helps doctors understand risk factors so they can better predict and manage the disease.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This study follows people who have been confirmed to have fatty liver disease seen on a liver sample. It aims to understand the condition over time and how different causes and health factors may affect it.
This study looks at what drives non-alcoholic fatty liver disease and how it affects the body, including immune-related changes. You may be invited if you have confirmed fatty liver disease or, alternatively, if you are a healthy person with no liver disease.
This study looks at better ways to predict significant liver fibrosis (scarring) in people with chronic hepatitis B or non-alcoholic fatty liver disease. It aims to help avoid invasive tests like liver biopsy.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.